SCIENTIFIC PROGRAMME
SESSION I
BIOLOGY OF B-CELL
PRECURSOR ALL
SESSION II
BIOLOGY OF T-CELL ALL
SESSION III
MINIMAL RESIDUAL
DISEASE MONITORING
SESSION IV
INDIVIDUALIZED
MANAGEMENT OF ALL
SESSION V
NEW ADVANCES IN ALL
SESSION VI
CAR T-CELLS &
ALLOGENEIC HSCT
SESSION VII
FRONTLINE
INCORPORATION OF
BITES AND ADCS
SESSION VIII
T-CELL ALL AND
LYMPHOBLASTIC
LYMPHOMA
SESSION IX
PH AND PH-LIKE ALL
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
AS E-POSTERS
DISCLOSURES
potential role of OPN in T-ALL for the first time. Upregulation of CD44 and OPN identify
potential therapeutic targets for KMT2Ar T-ALL, as CD44 therapeutic monoclonal antibodies
are currently in development. Further exploration of the role of CD44 and OPN expression in
KMT2Ar T-ALL is warranted to understand the molecular mechanisms of disease, to inform
targeted therapeutic strategies and ultimately improve patient outcomes for this aggressive
malignancy.
